NeoGenomics, Inc. (NEO)

Market Cap	1.79B
Revenue (ttm)	591.64M
Net Income (ttm)	-87.97M
Shares Out	127.67M
EPS (ttm)	-0.70
PE Ratio	n/a
Forward PE	222.22
Dividend	n/a
Ex-Dividend Date	n/a

Volume	518,778
Open	14.12
Previous Close	14.16
Day's Range	13.81 - 14.29
52-Week Range	11.03 - 21.22
Beta	1.10
Analysts	Strong Buy
Price Target	19.50 (+38.99%)
Earnings Date	Apr 30, 2024

About NEO

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detect...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Nov 2, 1999
• Employees: 2,100
• Stock Exchange: NASDAQ
• Ticker Symbol: NEO

Financial Performance

In 2023, NeoGenomics's revenue was $591.64 million, an increase of 16.07% compared to the previous year's $509.73 million. Losses were -$87.97 million, -39.02% less than in 2022.

Analyst Forecast

According to 9 analysts, the average rating for NEO stock is "Strong Buy." The 12-month stock price forecast is $19.5, which is an increase of 38.99% from the latest price.

Price Target

$19.5

(38.99% upside)

Analyst Consensus: Strong Buy